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with ezetimibe is more limited, the profile to date is very
encouraging, particularly with respect to the lack of any incremen-
tal risk with respect to the most worrisome statin-related side
effects, namely myopathy and rhabdomyolysis. Thus, considering
the large numbers of patients not at NCEP ATP III therapeutic
goals as well as the well-recognized reluctance of many physicians
to titrate, I believe that co-administration of ezetimibe with
low-dose statins provides a valuable new option for treatment of
hypercholesterolemia.
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REPLY
I thank Dr. Davidson for clarifying some of the estimates for low
density lipoprotein (LDL) reduction that I computed for statin
and ezetimibe doses (1). Although we do have treatment goals for
LDL cholesterol (LDL-C), it is worth emphasizing that it is risk
reduction that is the ultimate goal. The additional risk reduction
expected from two doublings of a statin dose or from ezetimibe
remains modest in typical patients, about 15% for a patient with a
pretreatment LDL-C of 190 mg/dl, and 12% when the pretreat-
ment LDL-C is 140 mg/dl. This reflects the modest efficacy of
ezetimibe, a 14% lowering of LDL-C shown in Dr. Davidson’s
excellent study (2), and of two doublings of statin doses. This
magnitude is consistent with much of the literature on the drug.
The added value in terms of risk reduction appears rather modest
and needs to be balanced against the cost, lack of long-term
outcome data, and need for other medications, particularly in older
patients.
My perspective is that the benefits and safety of statin therapy
are very well established, and I favor its use across the approved
dose ranges. I am finding ezetimibe useful in combination with 40
mg or 80 mg of a statin in patients with moderate to severe
hypercholesterolemia for whom more substantial risk reduction
should occur from additional LDL reduction. I am much less
convinced that adverse effects of statin therapy truly occur in more
than a very few patients. I base this on results of trials that compare
adverse effects reported during statin therapy with those during
placebo treatment in tens of thousands of patients (3,4). Myalgia is
a common feature of the human condition, inexorably increasing
with aging. When patients complain of myalgias while taking
statins, it is important to ensure that it fits the clinical features of
statin-myopathy, following the accepted guidelines for this diag-
nosis (5). Whether ezetimibe or other nonstatin LDL-lowering
drugs like colesevelam offer a useful alternative in “statin intoler-
ant” patients remains to be determined.
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